Neuberger Berman Group
CLSD

Neuberger Berman Group’s Clearside Biomedical CLSD Stock Holding History

Neuberger Berman Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,667
Closed -$224K – 1593
2016
Q4 		$224K Buy
+1,667
New +$418K ﹤0.01% 1494

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Neuberger Berman Group's CLSD Position: Q1 2017 in Review

Neuberger Berman Group sold out of Clearside Biomedical (CLSD) in Q1 2017, closing a stake of 1,667 shares — an estimated $224K sold.

Neuberger Berman Group first reported a position in CLSD in Q4 2016 and held it in 1 quarter. The position peaked at $224K in Q4 2016. 59 funds tracked by Wall St. Rank hold CLSD as of Q1 2017.

  • Neuberger Berman Group reported no remaining Clearside Biomedical position as of Q1 2017 after selling out during the quarter.
  • Neuberger Berman Group sold 1,667 Clearside Biomedical shares in Q1 2017, an estimated $224K.
  • Neuberger Berman Group first reported a position in Clearside Biomedical in Q4 2016 and held it in 1 quarter.
  • Neuberger Berman Group's Clearside Biomedical position peaked at $224K in Q4 2016.
  • 59 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2017.

Based on Neuberger Berman Group's 13F filing for Q1 2017, filed 10 May 2017.